These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27697749)

  • 1. ENHANCE-(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease.
    Creary S; Chisolm DJ; O'Brien SH
    JMIR Res Protoc; 2016 Oct; 5(4):e193. PubMed ID: 27697749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
    Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
    JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
    Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
    BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.
    Sasi P; Makubi A; Sangeda RZ; Ngaeje MY; Mmbando BP; Soka J; Rosano C; Magesa AS; Cox SE; Makani J; Novelli EM
    Commun Med (Lond); 2024 Aug; 4(1):160. PubMed ID: 39122788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
    Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
    BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
    Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
    Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
    [No Abstract]   [Full Text] [Related]  

  • 11. Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial.
    Sekandi JN; Onuoha NA; Buregyeya E; Zalwango S; Kaggwa PE; Nakkonde D; Kakaire R; Atuyambe L; Whalen CC; Dobbin KK
    JMIR Res Protoc; 2021 Jan; 10(1):e18029. PubMed ID: 32990629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
    Yang M; Elmuti L; Badawy SM
    Biomed Res Int; 2022; 2022():2122056. PubMed ID: 35898672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.
    Inoue S; Kodjebacheva G; Scherrer T; Rice G; Grigorian M; Blankenship J; Onwuzurike N
    Int J Hematol; 2016 Aug; 104(2):200-7. PubMed ID: 27225236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.
    Badawy SM; DiMartino L; Brambilla D; Klesges L; Baumann A; Burns E; DeMartino T; Jacobs S; Khan H; Nwosu C; Shah N; Hankins JS;
    JMIR Form Res; 2022 Oct; 6(10):e41415. PubMed ID: 36240004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life.
    Anderson LM; Leonard S; Jonassaint J; Lunyera J; Bonner M; Shah N
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27081. PubMed ID: 29693797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
    Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
    Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.
    Jose J; Elsadek RA; Jimmy B; George P
    Oman Med J; 2019 Jul; 34(4):327-335. PubMed ID: 31360322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
    Hankins JS; Brambilla D; Potter MB; Kutlar A; Gibson R; King AA; Baumann AA; Melvin C; Gordeuk VR; Hsu LL; Nwosu C; Porter JS; Alberts NM; Badawy SM; Simon J; Glassberg JA; Lottenberg R; DiMartino L; Jacobs S; Fernandez ME; Bosworth HB; Klesges LM; Shah N
    Blood Adv; 2023 Dec; 7(23):7190-7201. PubMed ID: 37738155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.